Incomplete Recovery of Pneumococcal CD4 T Cell Immunity after Initiation of Antiretroviral Therapy in HIV-Infected Malawian Adults by Sepako, Enoch et al.
Incomplete Recovery of Pneumococcal CD4 T Cell
Immunity after Initiation of Antiretroviral Therapy in HIV-
Infected Malawian Adults
Enoch Sepako1,2*, Sarah J. Glennie1,5, Kondwani C. Jambo1,2, David Mzinza1,
Oluwadamilola H. Iwajomo1,4,5, Dominic Banda1, Joep J. van Oosterhout3, Neil A. Williams5,
Stephen B. Gordon2, Robert S. Heyderman1
1Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi, 2 Respiratory Infection Group, Liverpool
School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom, 3Dignitas International, Zomba, Malawi, 4Division of Clinical Sciences, University of Toronto,
Ontario, Canada, 5Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
Abstract
HIV-infected African adults are at a considerably increased risk of life-threatening invasive pneumococcal disease (IPD)
which persists despite antiretroviral therapy (ART). Defects in naturally acquired pneumococcal-specific T-cell immunity
have been identified in HIV-infected adults. We have therefore determined the extent and nature of pneumococcal antigen-
specific immune recovery following ART. HIV-infected adults were followed up at 3, 6 and 12 months after initiating ART.
Nasopharyngeal swabs were cultured to determine carriage rates. Pneumococcal-specific CD4 T-cell immunity was assessed
by IFN-c ELISpot, proliferation assay, CD154 expression and intracellular cytokine assay. S. pneumoniae colonization was
detected in 27% (13/48) of HIV-infected patients prior to ART. The rates remained elevated after 12 months ART, 41% (16/39)
(p = 0.17) and significantly higher than in HIV-uninfected individuals (HIVneg 14%(4/29); p = 0.0147). CD4+ T-cell proliferative
responses to pneumococcal antigens increased significantly to levels comparable with HIV-negative individuals at 12
months ART (p = 0.0799). However, recovery of the pneumococcal-specific CD154 expression was incomplete (p = 0.0015) as
were IFN-c ELISpot responses (p = 0.0040) and polyfunctional CD4+ T-cell responses (TNF-a, IL-2 and IFN-c expression)
(p = 0.0040) to a pneumolysin-deficient mutant strain. Impaired control of pneumococcal colonisation and incomplete
restoration of pneumococcal-specific immunity may explain the persistently higher risk of IPD amongst HIV-infected adults
on ART. Whether vaccination and prolonged ART can overcome this immunological defect and reduce the high levels of
pneumococcal colonisation requires further evaluation.
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Introduction
Invasive pneumococcal disease (IPD), in the form of pneumo-
nia, bacteraemia and meningitis is a leading cause of mortality
worldwide [1,2]. HIV-infected adults and children are 20 to 100
times more likely to suffer invasive pneumococcal disease than
age-matched HIV negative persons [3,4,5].
Natural protective immunity to Streptococcus pneumoniae is thought
to rely at least in part on antigen-specific T-cell memory that acts
through antibody-dependent and independent pathways that can
be rapidly mobilised to mediate microbial clearance at the
mucosal surface as well as interrupt multiplication following
bloodstream invasion [6,7,8,9]. We have previously shown that
mucosal CD4 T-cell immunity to pneumococcal protein antigens
is acquired with age and is tightly regulated by antigen-specific
CD4+CD25hi T regulatory cells [6]. In African high colonisation
settings, CD4 T-cell immune memory to these pneumococcal
antigens is very commonly detectable in the peripheral blood of
adults [10] but appears to be highly susceptible to HIV-mediated
immune disruption. Indeed, we have reported that pneumococ-
cal–specific T and B-cell immunity is compromised in HIV-
infected Malawian individuals, where there is a high frequency of
pneumococcal exposure [11,12]. We have shown that even in
asymptomatic HIV-infected Malawian adults (WHO stage I)
pneumococcal-specific interferon–gamma (IFN-c)-mediated CD4
T-cell effector memory and CD4 T-cell central memory prolifer-
ative responses are impaired whilst intrinsic proliferative capacity
to PHA remained intact [11]. Although, reconstitution of
immunity in general occurs following initiation of antiretroviral
therapy (ART) [13,14], IPD is still 30 times greater in HIV
positive persons on ART compared to uninfected individuals
[15,16].
This suggests that following ART, reconstitution of immunity
specific to S. pneumoniae may be incomplete. Indeed in a cross-
sectional study, we have recently shown striking increases in
pneumococcal colonization with a broad range of serotypes during
the progression of HIV infection in adults [17]. These were
associated with dynamic changes in peripheral pneumococcal-
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specific Th1 IFN-c immunity which together with these high levels
of colonisation did not appear to fully resolve during immune
reconstitution with ART.
However, it is important to recognise that the cross-sectional
design of our previous study may have led to misleading
comparisons between participants with widely differing CD4
nadir’s, patterns of pre-ART opportunistic infection and responses
to treatment in an African setting. We have therefore investigated
the impact of ART on naturally-acquired CD4 T-cell mediated
immunity to pneumococcal protein antigens in a prospective
longitudinal study of otherwise healthy HIV-infected Malawian
adults, using a wider array of functional assays to map out the
kinetics and the degree of immune reconstitution, and their
relationship to nasopharyngeal carriage of S. pneumoniae.
Materials and Methods
Ethics Statement
This study complied with institutional practices and guidelines
and was approved by the University of Malawi, College of
Medicine (Protocol No. P.07/09/801) and Liverpool School of
Tropical Medicine (LSTM, Protocol No. 09.71) research ethics
committees. Samples (peripheral blood and nasopharyngeal swabs)
were obtained following written-informed consent.
Study design
48 HIV-positive adults initiating ART were recruited from the
ART clinic at Queen Elizabeth Central hospital in Blantyre,
Malawi and followed up at 3, 6 and 12 months. Eligibility for ART
was based on WHO stage 3/4 disease or a CD4 count,250 cells/
ml (the cut-off used in Malawi at the time of recruitment).
Participants were excluded from the study if they were: febrile
(axillary temperature$38.0uC) or unwell; had unexplained weight
loss, recurrent respiratory infections, acute Herpes zoster, TB or
cryptococcal disease in the past 6 months; were already on ART;
had other immunocompromising illness (e.g. diabetes, chronic
liver disease, chronic renal impairment, malignancy); known or
possible pregnancy; severe anemia (Hb ,8 g/dl) or were taking
immunosuppressant drugs (e.g. corticosteroids). Samples were also
collected from 29 HIV-uninfected healthy individuals (from the
same community) and were used to assess the degree of immune
reconstitution in the HIV-infected individuals at 12 months ART.
Plasma HIV-1 Viral load measurement
HIV-1 RNA levels in blood plasma were measured using the
Abbot Real-Time HIV-1 assay in a subset of randomly selected
participants. Samples were prepared manually and viral load
quantified on the Abbot m2000- rt instrument (Abbott Molecular,
Germany), according to the manufacturer’s instructions (detection
level 50 copies/ml).
Assessment of pneumococcal colonization
Pneumococcal carriage was evaluated using the World Health
Organisation standard protocol for detecting nasopharyngeal
pneumococcal colonisation [18]. Nasopharyngeal swabs were
obtained and immediately placed into a vial of skim milk-tryptone-
glucose-glycerol (STGG) transport medium. In the laboratory, the
nasopharyngeal swab specimen in STGG media was mixed
thoroughly and plated onto a gentamicin (2.5 mg/ml) sheep blood
agar (BA) for the isolation of S. pneumoniae. The plate was incubated
at 37uC, 5% CO2 overnight and pneumococci identified by their
morphology (alpha-haemolytic colonies) and optochin susceptibil-
ity. Susceptibility to optochin was defined as the diameter of
inhibition zone. Zones of inhibition greater than 14 mm indicated
susceptibility, 7 to 13 mm indicated indeterminate and less than
7 mm as resistant to optochin. Isolates that were susceptible to
optochin were considered pneumococci and those that were
resistant to optochin were considered to be species other than
pneumococcus.
Cells and Antigens
PBMCs were isolated from blood by 25 minutes centrifugation
at 400 g on a density-gradient (Histopaque, Sigma). PBMCs were
harvested, washed in hanks balanced salt solution (HBSS,
Invitrogen, Paisley, UK) at 400 g for 10 min, and resuspended
in complete RPMI (RPMI-1640 with 100 U/ml penicillin,
0.1 mg/ml streptomycin, 4 mM LL-glutamine and 10 mM
HEPES buffer). PBMCs were counted using 0.4% (wt/vol) trypan
blue (Sigma), reconstituted in complete RPMI at a concentration
of 16106 cells/ml; with a final concentration of 2% (vol/vol) heat-
inactivated human AB serum (National Blood Services, Blantyre)
[11].
Pneumococcal culture supernatants were prepared from a
standard encapsulated type 2 (D39) S. pneumoniae strain and an
isogenic pneumolysin-deficient mutant (Ply-; was kindly provided
by James Paton [19]). The pneumococcal strain was grown on
blood agar plates. Colonies showing a-haemolytic pneumococcal
type growth and optochin (an antibiotic) sensitivity were then
cultured in Todd-Hewitt broth (Oxoid, UK) supplemented with
0.5% yeast extract (THY) in 5% CO2 at 37uC to exponential
phase, filtered and concentrated. Bradford protein assay was used
to measure the concentration of the concentrated pneumococcal
culture supernatants (CCS). The concentrated culture superna-
tants were heat-inactivated at 56uC for 30 minutes to reduce toxic
effects of pneumococcal proteins (in the absence of heat
inactivation toxicity frequently inhibited proliferative capacity).
The absence of Ply in the mutant supernatant was confirmed by
discontinuous sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis and western immunoblotting [10]. The culture
supernatants were used at a final concentration of 8 mg/ml.
Mycobacterium tuberculosis purified protein derivative (10 mg/ml;
PPD RT50) obtained from Statens Serum Institut (Copenhagen,
Denmark) and Influenza antigens (0.9 mg/ml) derived from
dialyzed inactive trivalent split virion influenza vaccine (2009/
2010 vaccine; Sanofi Pasteur MSD Limited, UK) served as
reference (respiratory pathogens) controls. Due to limitations in
PBMC numbers, not all assays were done on all the subjects at
every time point.
Phenotyping of T cell subsets
200 ml of peripheral blood was stained extracellularly at room
temperature in the dark for 10 min with a combination of
antibodies specific to each of the three T-cell phenotype groups
being assessed (naive/memory T cells, Tregs and Senescent T
cells). A combination of CD3 PerCP, CD45RA PE, CD8 APC-
Cy7, CD4 APC and CCR7 PE-Cy7 antibodies all from BD
Biosciences was used to stain for naive/memory T cells. CD3
PerCP, CD4 pacific blue, CD25 FITC antibodies (BD Biosciences)
were used for Tregs. For senescent T cells, peripheral blood was
stained with anti-CD3 FITC, anti-CD28 PE, anti-CD4 pacific
blue, anti-CD57 APC and anti-CD8 PerCP (BD Biosciences).
After surface staining, red blood cells were lysed with 16FACS
Lysing solution (BD Biosciences) and the cells washed with 16
PBS. The cells surface-stained for Tregs were then permeabilised
and fixed using 16 Foxp3 Fixation/Permeabilization working
solution as per manufacturer’s instructions (ebioscience). After
washing with 16 Perm wash (ebioscience), the cells were stained
intracellularly with an anti-Foxp3 PE (ebiosciences). The cells were
Pneumococcal T-Cell Immunity following ART
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acquired on either a FACSCalibur (BD Biosciences) or a Cyan
ADP flow cytometer (Beckman Coulter). Approximately 60 000
events were acquired within the lymphocyte gate.
Data were analyzed with either FlowJo software (TreeStar Inc,
Stanford University, FlowJo Africa scheme) or Summit software
version 4.3.2 (Beckman Coulter). Lymphocytes were gated based
on forward scattering (FSC) and side scattering (SSC) and CD3+,
CD82, and CD4+ cells were considered to be CD4 T cells. These
CD4+ T cells were analysed for Foxp3+ CD25high cells (Tregs),
CD45RA and CCR7 expression [naive/memory cells: TCM
(CCR7+ CD45RA2), TEM (CD4
+ CCR72 CD45RA2) and naı¨ve
CD4 T cells (CCR7+ CD45RA+)] and CD57+CD282 cells
(senescent T cells). Absolute counts of CD4 T lymphocytes were
enumerated using BD FACSCount reagent kit (CD4/CD8/CD3)
on a BD FACSCount instrument (BD Biosciences).
IFN- c enzyme-linked immunosorbent spot (ELISPOT)
Assay
Freshly isolated PBMCs were assayed for cells producing IFN-c,
using an ELISPOT assay as previously described [11]. Briefly,
Multiscreen HTS 96-Well Filtration plates (Millipore) were coated
with 15 ug/ml anti-human IFN-c mouse monoclonal antibody (1-
D1K; Mabtech) in sterile PBS for 4 hours at room temperature.
The plates were washed with 16 sterile PBS to remove unbound
coating antibody and blocked for 1 hour with 200 ml RPMI
supplemented with 10% fetal calf serum (Sigma). PBMCs
suspended in complete media were seeded at 0.56106 cells/well
in duplicate wells and incubated with or without antigen for
18 hours at 37uC, 5% CO2. Cells were stimulated with D39WT
CCS (8 mg/ml), D39Ply- CCS (8 mg/ml). 10 mg/ml PPD (Statens
Serum Institute) and 0.9 mg/ml influenza vaccine, split-virion
inactivated (2009/2010 vaccine; Sanofi Pasteur MSD Limited
UK) were used as reference antigen controls and 5 mg/ml PHA-L
(Sigma-Aldrich) as a mitogenic control.
After 18 hours of incubation, the plates were first washed with
16sterile PBS containing 0.05% TWEEN 20 (Sigma-Aldrich) and
then sterile 16PBS. 1 ug/mL of biotinylated anti–human IFN-c
antibody 7-B6-1 (MABTECH) diluted in 0.5% fetal calf serum
plus 16 PBS was added to each well followed by incubated for
2 hours at room temperature. After washing, the cells were
incubated with 1 mg/ml of streptavidin-alkaline phosphatase
conjugate (Mabtech) for 1 hour at room temperature to detect
spot-forming cells (SFCs). Thereafter, the plates were developed
using a chromogenic alkaline phosphatase substrate kit (Bio-Rad)
as per manufacturer’s instruction. Spot forming cell numbers were
counted using an ELISPOT plate reader (AutoImmuneDiagnos-
tica, Vers. 4.0). The results were expressed as spot forming units
(SFU) per a million PBMCs after subtraction of individual media
only background values.
Proliferation Assay
Lymphocyte proliferation assay was performed as previously
described [11]. 126106 freshly isolated PBMCs were labelled with
carboxyfluorescein diacetate 5,6 succinimidyl ester (CFSE dye)
(final concentration 1.25 mM, Invitrogen) for 8 minutes at 37uC in
the dark. Next, CFSE staining was stopped using 200 ml of fetal
bovine serum (Sigma-Aldrich). After washing the cells were
resuspended in complete RPMI (RPMI 1640 supplemented with
penicillin/streptomycin (concentration, 100 U/mL), L-glutamine
(4 mmol/L), HEPES, (10 mmol/L; Sigma-Aldrich) and 2% (vol/
vol) of heat-inactivated human AB serum (National blood Services,
Blantyre, Malawi).
Labelled cells were cultured at 0.86106 cells/ml in a 48-well
plate with D39WT CCS (8 mg/ml), D39Ply- CCS (8 mg/ml), PPD
(10 mg/ml), Influenza (0.9 mg/ml), PHA (5 mg/ml) or media only
for 8 days at 37uC, 5% CO2. Cells were harvested and stained
with anti-CD4-APC and anti-CD8-Percp (BD Biosciences).
Finally, the cells were washed with 16 PBS and re-suspended in
FACS flow and acquired using the Cell Quest Pro software
(version 5.2.1) on a four-colour flow cytometer (BD FACSCalibur).
60 000 events in the lymphocyte gate were acquired. Data were
analysed with FlowJo software (TreeStar Inc, Stanford University,
FlowJo Africa scheme). Antigen-specific T-cell proliferation was
expressed as the percentage of CD4+ T cells.
Detection of CD154 expression as measured by surface
mobilization Assay
CD154 expression was measured using a co-culture method as
previously described [11,20]. 1.5–26106 freshly isolated PBMCs
were plated in a 96-well plate in 200 ml RPMI 1640 medium
(Sigma-Aldrich) supplemented with 2% heat inactivated AB
human serum (National Blood Services, Blantyre, Malawi),
2 mM L-glutamine, 100 U/ml penicillin, 20 mM HEPES buffer
and 100 ug/ml streptomycin (Sigma). An anti-CD154-phycoery-
thrin (PE) antibody was added to every well immediately before
stimulation as previously described [20].
The cells were stimulated with D39WT CCS (8 mg/ml),
D39Ply- CCS (8 mg/ml), PPD (10 mg/ml), Influenza (0.9 mg/ml),
PHA (5 mg/ml) or media only at 37uC, 5% CO2 for 16 hours. No
costimulatory molecules were added. After stimulation, cells were
harvested, washed with PBS and surface-stained with anti-CD3
fluorescein isothiocyanate (FITC), anti- CD4 peridinin chlorophyll
protein (PerCP), anti-CD69 allophycocyanin (APC) for 15 min at
4uC in the dark. The cell were then washed with 1 ml 16 sterile
PBS and resuspended in FACS flow. The cells were acquired using
the Cell Quest Pro software (version 5.2.1) on a four-colour flow
cytometer (BD FACSCalibur). Data were analyzed with FlowJo
software (TreeStar Inc, Stanford University, FlowJo Africa
scheme) by initially gating on lymphocytes followed by CD3 then
CD4+ cells. CD154 expression was examined on CD69+ CD4+ T
cells.
Intracellular Cytokine Staining
Intracellular cytokine assay was performed on fresh PBMCs as
previously described [21]. 1.56106 freshly isolated PBMCs were
plated in a 96-well plate in 200 ml RPMI 1640 medium
supplemented with 2% heat inactivated AB human serum,
2 mM L-glutamine, 100 U/ml penicillin, 20 mM HEPES buffer
and 100 mg/ml streptomycin (Sigma).
The cells were stimulated with pneumococcal cell culture
supernatants (8 mg/ml) and Purified Protein Derivative (PPD,
10 mg/ml [Statens Serum Institute, Denmark) and influenza
vaccine, split-virion inactivated (2009/2010 vaccine; Sanofi
Pasteur MSD Limited UK) which were used as reference controls
and PMA (10 ng/ml) plus ionomycin (1 mg/ml) (Sigma, St Louis,
MO) and incubated at 37uC in the presence of 5% CO2.
Brefeldin A (10 mg per ml) (BD Bioscience, UK) was added at
2 h of incubation and the cells were cultured for an additional
16 hr at 37uC, 5% CO2. Negative control wells were left
unstimulated in all experiments. No costimulatory molecules were
added. After stimulation, the cells were harvested, washed and
stained with Violet Viability dye (LIVE/DEAD Fixable Dead Cell
Stain kit, Invitrogen, UK) for dead cell discrimination as per the
manufacturer’s instructions. Cells were then stained at 4uC for 15
minutes with surface marker antibodies: CD4 APC-H7and CD8
PerCP all from BD Biosciences.
Next, the cells were washed, permeabilised and fixed using
Cytofix/Cytoperm solution (BD Bioscience, UK) as per the
Pneumococcal T-Cell Immunity following ART
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manufacturer’s instructions. The cells were then stained with anti-
IFN-c APC, anti-TNF-a Alexa Fluor 488 and anti- IL-2 PE (all
BD Bioscience, UK) to detect intracellular cytokines. Finally, the
cells were washed with 16Perm Wash (BD Bioscience, UK) and
re-suspended in FACS flow. The cells were acquired on a 9 colour
Cyan ADP flow cytometer (Beckman Coulter, USA). At least 100
000 lymphocytes were acquired. Cell doublets were excluded using
forward light scatter–area vs forward light scatter-height param-
eters and dead cells discriminated by ViViD. Data were analyzed
with FlowJo software (TreeStar Inc, Stanford University, FlowJo
Africa scheme) and subsequent analysis was performed using
Simplified Presentation of Incredibly Complex Evaluations
(SPICE, version 4 (NIAID/NIH,USA); responses were back-
ground subtracted and threshold was set at 0.01%). Unstimulated
cells were used to set cut-off gates for cytokines.
Statistical analysis
Statistical analyses and graphical presentation were done using
GraphPad Prism 5 (GraphPad). The presence or absence of
nasopharyngeal pneumococcal colonization in HIV-infected and
uninfected individuals were analyzed using Fishers exact test.
Mann-Whitney U test was used for non-paired and Wilcoxon sign
ranked test for paired data that was not normally distributed.
Differences were considered statistically significant where P,0.05.
Results
Baseline and follow-up characteristics of study
participants
A total of 48 HIV-positive patients initiating ART were enrolled
(median age 37 years; [range of 25–55 years]: 21 (44%) males
(Table 1). All patients started on a generic antiretroviral drug
combination of stavudine, lamivudine and nevirapine as well as
prophylaxis with cotrimoxazole. During the 12 months post-ART
initiation follow-up period, 2 participants died and 6 were lost to
follow up. Two patients changed ART regimen due to side-effects.
HIV-uninfected persons (29) had similar age and sex distribution
to HIV-infected individuals with a systemic median of absolute
CD4+ T cell count of 602 (range 329–1410) cells/ml.
The median baseline, pre-ART absolute CD4+ T-cell count was
161 cells/ml (range 3–573 cells/ml). Baseline CD4+ T-cell count
categories were: 15 patients had CD4+ T-cell counts #100 cells/
ml; 18 had CD4+ cell counts between 101 and 200 cells/ml, 8 had
CD4+ T-cell counts between 201 and 350 cells/ml and 6 had
CD4+ T-cell counts .350 cells/ml. The median CD4 T-cell count
increased to 275 cells/ml (range: 73–699) at 12 months of ART
(p,0.001) (Table 1), but remained significantly lower compared
to the HIV-negative individuals (Figure 1A; median 275 cells/ml
vs 602 cells/ml, p,0.0001). The increase in the CD4+ T-cell count
was most rapid during the first 3 months of therapy (Figure 1A;
p,0.0001).
Nasopharyngeal carriage of S. pneumoniae was detected in 27%
(13/48) of study participants at enrolment, increasing but not
significantly to 33% (14/43), 40% (17/40) and 41% (16/39) at
months 3, 6 and 12 respectively (Table 1, p=0.17 (pre-ART vs
12 months ART)), but significantly lower than carriage rates in
HIV-uninfected individuals (HIVneg 14% (4/29), p = 0.0147[HIV-
neg vs. HIVpos12mthsART]). Viral loads were not routinely available
at the time of the study. Plasma HIV-1 RNA was determined for
27 participants (27/43) at 6 months ART. All participants had
HIV-1 RNA less than 5000 copies/ml. Eleven had undetectable
HIV-1 RNA, nine had 100 - 1000 copies/ml, four had 1000–2000
copies/ml and two had between 2000 and 4000 copies/ml.
Further viral load data were not available. However, all
participants adhered to a highly effective regimen (nevirapine,
stavudine and lamivudine) throughout the study period and none
of the patients developed any secondary infection or opportunistic
infection to suggest that HIV replication was not being suppressed.
Changes in CD4 T-cell phenotype during ART
Naive and memory T cells. We have previously shown that
in asymptomatic HIV-infected individuals (WHO Stage I), the
proportion of naive T cells is comparable to healthy HIV-negative
persons but memory cells are proportionally decreased [11]. We
now show no change in the proportion of naive CD4+ T cells
(CCR7+CD45RA+)[21,22] between 0 and 6 months ART-
mediated immune reconstitution but that this subset had further
increased by 12 months (Figure 1B, p = 0.0001), to levels even
higher to those seen in HIV–uninfected individuals (median
35.73% vs 19.36%, p = 0.0234). The proportion of central
memory T cells (CCR7+CD45RA2) remained significantly lower
and unchanged for the entire 12 month period compared to HIV-
negative individuals (Figure 1B, median 23.24% vs. 36.98%, p,
0.0001). In contrast, by 12 months ART, the elevated effector
Table 1. Baseline and follow-up characteristics of HIV-infected study participants.
Time on ART (months)
Pre-ART (0) 3 6 12 Pa
N 48 44 42 40
Age(Median, range, years) 37(25–55) NA NA NA
Male[No.%] 21(44) NA NA NA
CD4 counts
Median(range), cells/ml 161(3–573) 281(17–737) 249(63–760) 275(73–699) p,0.001
ARV Treatment [No.]
stavudine,lamivudine & nevirapine 46
zidovudine, lamivudine & nevirapine 1*
stavudine,l amivudine & efavirenz 1*
Pneumococcal Carriage [No.%] 13/48(27) 14/43(33) 17/42(40) 16/39(41) 0.17
a0 mth versus 12 mths ART *Changed ART regimen due to side-effects.
doi:10.1371/journal.pone.0100640.t001
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memory cell population (CCR72CD45RA2) had decreased
significantly (Figure 1B, p,0.0001[6 months vs. 12 months
ART]) to levels similar to those seen in HIV-uninfected individuals
(median 38.09% vs. 35.67%, p = 0.5046).
Senescent and Tregs CD4+ T cells. Chronic immune
activation and persistent infections in HIV-1 infected individuals
provides an environment that favours accelerated replicative
senescence of (CD4+CD282CD57+) T cells and expansion of
CD4+CD25hi+Foxp3+ regulatory T cells (Tregs) [11,23]. In this
African population, we found that the median percentages of
CD4+CD282CD57+ senescent T cells decreased after initiation of
ART (month 0: 1.87% [0?17–59?34%], 3 months ART: 1?02%
[0?02–26?26%, p = 0.0005] and 12 month ART: 0.92% [0?07–
15?45%]) (Figure 1C).
The proportion of senescent CD4+ T cells was comparable
between healthy HIV-uninfected and HIV-infected individuals at
12 months ART (Figure 1C, median 0.9200% vs. 0.4200,
p = 0.19). Before ART, median percentage of Tregs in HIV-
infected patients was 2?45% (0?95–7?5%) of CD4+ T cells. The
median percentages decreased following initiation of therapy
(1.13% [0.30–3.73] at 3 months ART, p,0.0001 and thereafter
remained relatively unchanged and significantly higher compared
to HIV-negative individuals (Figure 1D, median 1,140 vs.
0.6500%, p = 0.0041).
Functional analysis of CD4 T cells in peripheral blood of
adults on ART
Regeneration of pneumococcal-specific T-cell ELISpot
responses during ART. We have previously shown that the
number of IFN-c-producing cells in response to pneumococcal
antigens is low but detectable in healthy controls and is relatively
well preserved in asymptomatic HIV-infected persons [11]. We
now show that following initiation of ART, the number of IFN-c
producing cells responding to D39WT CCS (concentrated culture
supernatants) increased significantly by 3 months (Figure 2A,
p = 0.039). By 12 months ART, there was no significant difference
between responses detected in HIV-infected individuals and
healthy HIV-uninfected subjects (p = 0.1756). Using a CCS from
D39Ply-, an isogenic mutant that lacked the immunodominant
pneumococcal protein pneumolysin, ELISpot responses were
relatively unchanged for the first 6 months of observation
(Figure 2B, p = 0.13). By 12 months, responses to D39Ply- rose
substantially but remained significantly lower compared to HIV-
uninfected persons (p = 0.0040). There was no recovery in IFN-c
Figure 1. CD4+ T-cell phenotypes in peripheral blood of adults before and after antiretroviral therapy at 3, 6 and 12 months ART
and in healthy HIV-uninfected individuals. (A) expansion of CD4 T- cell counts (0mth, n = 43; 3mths, n = 43; 6mths, n = 41; 12mths, n = 34; HIV-,
23) (B) naive CD4+ T cells (TN: CD45RA+CCR7+), central memory CD4+ T cells (TCM: CD45RA-CCR7+) and effector memory CD4+ T cells (TEM: CD45RA-
CCR7-) (0mth, n = 35; 3mths, n = 34; 6mths, n = 34; 12mths, n = 26; HIV-, 29) (C) CD28-CD57+ senescent cells (0mth, n = 34; 3mths, n = 34; 6mths,
n = 39; 12mths, n = 20; HIV-, 10) (D) CD4+CD25hiFoxP3+ T regulatory cells (0mth, n = 33; 3mths, n = 30; 6mths, n = 30; 12mths, n = 22; HIV-,13) Black
horizontal bars represent median and IQRs. Wilcoxon matched pairs were used to compare T-cell characteristics of HIV-infected persons on ART over
time, and the Mann Whitney U test in the HIV-infected and HIV-uninfected comparisons. Representative flow cytometric data demonstrating gating
strategy are shown in Figure S1.
doi:10.1371/journal.pone.0100640.g001
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effector responses to the reference control antigens, PPD and
influenza (Figure 3A and B; p,0.0001 and p,0.0001 respec-
tively). Changes in any of the T cell responses that we report were
not dependent on pre-ART baseline CD4 T-cell count nadir or
nasopharyngeal carriage status (data not shown).
Pneumococcal-specific T-cell proliferative responses
after ART. Following the initiation of ART, the median
Figure 2. Pneumococcal-specific CD4+ T-cell responses in peripheral blood during ART. Patients were analysed prior to initiation of ART
and followed-up at 3, 6 and 12 mths ART for CD4+ T-cell responses. Responses from HIV-infected persons at 12 months ART were compared with HIV-
negative persons recruited from the same community (A) ex vivo IFN-c ELISpot responses to wild-type Streptococcus pneumoniae strain concentrated
culture supernatant (CCS) (D39WT CCS) (0mth, n = 36; 3mths, n = 36; 6mths, n = 26; 12mths, n = 10; HIV-, 21) (B) ex vivo IFN-c ELISpot responses to an
isogenic pneumolysin (ply)-deficient mutant (D39Ply- CCS) (0mth, n = 36; 3mths, n = 36; 6mths, n = 26; 12mths, n = 10; HIV-, 21) (C) proliferative
responses (8 day CFSE dilution assay) to D39WT CCS (0mth, n = 16; 6mths, n = 13; 12mths, n = 13; HIV-, 28) (D) proliferative responses to D39Ply- CCS
(0mth, n = 17; 6mths, n = 14; 12mths, n = 13; HIV-, 28) (E) CD154 expression on activated CD4+ T cells in response to D39WT CCS (0mth, n = 33; 3mths,
n = 30; 6mths, n = 30; 12mths, n = 16; HIV-, 29) (F) CD154 expression on activated CD4+ T cells in response to D39Ply- CCS (0mth, n = 30; 3mths, n = 29;
6mths, n = 28; 12mths, n = 14; HIV-, 29). Black horizontal bars represent median and IQR after background responses were substrated from all antigen-
specific CD4+ T cell responses. Wilcoxon matched pairs were used to compare T-cell characteristics of HIV-infected persons on ART over time, and the
Mann Whitney U test in the HIV-infected and HIV-uninfected comparisons. Representative flow cytometric data demonstrating CD4+ T-cell
proliferative responses and CD154 expression and gating strategy are shown in Figure S1.
doi:10.1371/journal.pone.0100640.g002
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proportion of proliferating CD4+ T cells in response to D39WT
CCS increased significantly from 2.197% (IQR, 0.063–5.65) at
baseline to 5.88% (2.50–8.38) after 6 months ART (Figure 2C,
p = 0.033). By 12 months, the proportion of proliferating CD4+ T
cells was comparable between healthy HIV-uninfected and HIV-
infected individuals (Figure 2C, p = 0.0799). Immune recovery to
Figure 3. Antigen (PPD and Flu)-specific CD4+ T-cell responses in peripheral blood during ART. Patients were analysed prior to initiation
of ART and followed-up at 3, 6 and 12 mths ART for CD4+ T-cell responses. Responses from HIV-infected persons at 12 months ART were compared
with HIV-negative persons recruited from the same community (A) ex vivo IFN-c ELISpot responses to M.tuberculosis PPD (0mth, n = 36; 3mths, n = 36;
6mths, n = 26; 12mths, n = 10; HIV-, 24) (B) ex vivo IFN-c ELISpot responses to influenza antigens (0mth, n = 36; 3mths, n = 36; 6mths, n = 26; 12mths,
n = 10; HIV-, 24) (C) proliferative responses (8 day CFSE dilution assay) to M.tuberculosis PPD (0mth, n = 12; 6mths, n = 12; 12mths, n = 12; HIV-, 28) (D)
proliferative responses to influenza antigens (0mth, n = 14; 6mths, n = 12; 12mths, n = 13; HIV-, 28) (E) CD154 expression on activated CD4+ T cells in
response to M.tuberculosis PPD (0mth, n = 33; 3mths, n = 30; 6mths, n = 30; 12mths, n = 16; HIV-, 29) (F) CD154 expression on activated CD4+ T cells in
response to influenza antigens (0mth, n = 30; 3mths, n = 28; 6mths, n = 30; 12mths, n = 16; HIV-, 29). Black horizontal bars represent median and IQR
after background responses were substrated from all antigen-specific CD4+ T-cell responses. Wilcoxon matched pairs were used to compare T cell
characteristics of HIV-infected persons on ART over time, and the Mann Whitney U test in the HIV-infected and HIV-uninfected comparisons.
Representative flow cytometric data demonstrating CD4+ T cell proliferative responses and CD154 expression and gating strategy are shown in
Figure S1.
doi:10.1371/journal.pone.0100640.g003
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D39Ply- CCS was slower but after 12 months ART there was no
significant difference between HIV-infected patients and HIV-
uninfected controls (Figure 2D, p = 0.6161). There were no
significant differences between proliferative responses of HIV-
infected patients and HIV-uninfected persons in response to PPD
and influenza antigens even after 12 months of ART (Figure 3C
& D respectively).
Impaired immune reconstitution of pneumococcal-
induced CD154 expression on CD4+ T cells during
ART. Expression of CD154, a key mediator of T cell-B cell/
APC cross-talk, on activated CD4+ T cells (CD4+CD69+ T cells) in
response to pneumococcal protein antigens is impaired in HIV
infected individuals [11]. Therefore, we investigated whether ART
restores this function. By 6 months of ART, the frequency of
activated CD4+ T cells expressing CD154 in response to D39WT
CCS gradually increased compared to baseline (Figure 2E,
p = 0.05). However, the expression of CD154 in response to
D39WT CCS and D39Ply- CCS in HIV-infected persons at 12
months ART were significantly lower compared to HIV-uninfect-
ed group (Figure 2E and F; p = 0.0015 and p = 0.0016
respectively).
There was little or no recovery of CD154 expression in response
to M. tuberculosis PPD even after 12 months of ART (Figures 3E,
p,0.0001), but influenza responses had recovered to levels
comparable to the HIV-uninfected group (Figure 3F, p = 0.284).
Polyfunctional CD4+ T cell profile after ART. The
presence of T cells capable of simultaneously producing multiple
effector cytokines has been associated with productive immune
responses to some infections such as leishmaniasis, TB and HIV
[24,25,26,27]. However, T cells from HIV-infected persons tend
to have impaired ability to simultaneously produce multiple
effector cytokines [28] and the frequency of antigen-specific
polyfunctional CD4+ T cells is reduced during HIV-infection [29].
Therefore, we examined the functionality of pneumococcal-
specific CD4+ T cells (TNF-a, IL-2 and IFN-c expression) prior
to and after initiation of ART.
At enrolment, neither D39WT nor D39Ply2-specific CD4+ T
cells co-expressed all cytokines (Figures 4A and 4B respectively).
The functional profile of D39WT-specific CD4+ T cells remained
unchanged longitudinally after initiation of ART and comparable
to the functionality of T cells from HIV-uninfected group.
However, D39Ply2-specific CD4+ T cells from HIV- negative
individuals had significantly more T cells producing more than
one cytokine simultaneously compared with T cells from HIV-
infected patients (Figure 4B, p = 0.004). No significant differences
in the CD4+ profile to PPD and Flu stimulation between 12
months ART and HIV-negative group (Figure 4C and D
respectively).
Discussion
HIV infection with or without progression to AIDS, significantly
increases the risk of invasive disease due to S. pneumoniae [30,31].
Recently, we showed that pneumococcal-specific T-cell immunity
is compromised in asymptomatic HIV-infected Malawian adults,
where there is a high frequency of pneumococcal exposure [11].
Here, we extend this previous observation to show the complex
pattern of incomplete immune reconstitution in HIV-infected
Malawian adults over the course of 12 months of ART. We
provide evidence for a defect in pneumococcal-specific CD154 (a
key mediator of T-cell/B cell/APC cross talk) expression, T-cell
polyfunctionality particularly when the immunomodulatory TLR
4 agonist, pneumolysin [32] was absent from the antigen
preparations employed. We also show persistent poor control of
pneumococcal nasopharyngeal colonisation.
In the context of CD4 T-cell absolute count recovery and viral
suppression, we have found an increase in the proportion of
CCR7+CD45RA+CD4+ naive T cells, a decrease in
CCR72CD45RA2CD4+ effector memory T cells and poor
recovery of CCR7+CD45RA2CD4+ central memory T cells.
These changes were associated with a reduction of CD4+ T-cell
senescence and a contraction of Tregs after 12 months of ART.
Together these findings are highly suggestive of a reduction but
not a complete resolution of the generalized immune activation
associated with uncontrolled HIV infection.
Despite increases in median CD4 count in subjects established
on ART, the rates of colonisation remained high. This is consistent
with our recent work which showed HIV-infected individuals who
have been on ART for at least 18 months have a significantly
higher S. pneumoniae carriage rate than HIV-negative persons [17].
Persistent high levels of pneumococcal carriage may be an
indication of compromised mucosal immunity (potentially a sign of
compromised URT epithelial function or dysregulation of innate
and adaptive immunity) which does not reconstitute as fast as
blood cellular immunity following initiation of ART. Compro-
mised mucosal immunity may increase the possibility of coloni-
zation by a wide range of invasive serotypes and therefore increase
vulnerability to IPD. In this study, we did not determine the
colonizing pneumococcal serotypes before initiation of ART,
whether the same serotypes persisted in patients during the course
of the 12 month ART or whether new serotypes were acquired
over time. Nonetheless, we have previously investigated serotype
composition change during ART in this population [17]. We
found that HIV-infected individuals carried a wider range of
invasive and non-invasive serotypes compared to HIV-negative
persons and that this remained unaltered by ART. In the context
of high levels of pneumococcal carriage, we speculate that our
study population represents an under-recognised reservoir for
genetic exchange and onward pneumococcal transmission.
There were no differences in immune responses between
carriers and non-carriers. However, it should be noted that our
analyses of carriage were entirely cross-sectional and therefore, do
not reflect the true carriage history of the carriers or noncarriers.
Additionally, we did not assess the frequency of colonization,
duration and density of the carriage events.
In the context of increased CD4 count, reduced antigen load
and by extension antigenic stimulation, together with reduced
immune activation (contraction of senescent and regulatory CD4
T cells), we show regeneration of pneumococcal-specific IFN-c
ELISpot responses (except D39Ply- responses) and CD4+ T-cell
proliferative responses. We have previously shown that ex vivo IFN-
c ELISpot pneumococcal responses are derived from
CD4+CD45RO+CCR72 effector memory cells [10]. Therefore,
a recovery of IFN-c responses reflects at least partial regeneration
of the pneumococcal-specific TEM function.
In healthy African populations, high levels of pneumococcal
carriage stimulate cellular immunity at the mucosal level which
can be detected in the blood [10]. Indeed in a cross-sectional
study, we have recently shown that increased colonization
coincided with dynamic changes in peripheral pneumococcal-
specific Th1 IFN-c immunity in HIV-symptomatic individuals
[17]. Whether the modest reconstitution of pneumococcal-specific
IFN-c ELISpot and proliferative T-cell responses seen in our study
population can be attributed at least in part to increases in
pneumococcal colonisation remains to be established.
We have demonstrated impaired upregulation of CD154 (a key
mediator of T-cell/B cell/APC cross talk). Given the changes in
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pneumococcal-specific IFN-c ELISpot and proliferative T-cell
responses following initiation of ART, the CD154 data somewhat
implicate defects in T-B signalling. Indeed, CD154 deficient T
cells homing to B follicles will fail to facilitate B- cell production of
pneumococcal-specific antibodies [33]. We also demonstrated
modest reconstitution of influenza-specific responses during ART
possibly due to less frequent and intense antigen exposure,
consistent with a previous study performed in the same setting
[34].
Given the selective regeneration of pneumococcal-specific T
cells even after 12 months of ART, such individuals may need
additional protection principally through vaccination. Because of
the suboptimal activity of the 23-valent pneumococcal polysac-
charide vaccine in HIV-infected African adults [35], routine
PPV23 vaccination of HIV-infected adults is not recommended for
use in resource poor countries [36]. A recent study in Malawi,
provided evidence that the 7-valent pneumococcal conjugate
vaccine (PCV) protected HIV-infected adults from recurrent
pneumococcal infection caused by vaccine serotypes, thus
supporting a role for conjugate vaccines among HIV-infected
adults [37].
Several studies have shown that following ART initiation, there
is often poor restoration of antigen-specific immune responses in
individuals who are severely immunodeficient prior to treatment
[38,39,40,41] However, although a low CD4 pre-treatment nadir
was common (68% of the study participants presented for the first
time with CD4 counts ,200 ml) there was no clear association in
our cohort.
T cells that produce multiple factors simultaneously (e.g. TNF-
a, IL-2 and IFN-c) are termed polyfunctional T cells and have
been shown to provide protection against diseases in murine
models of Leishmaniasis and TB [24,42], control of hepatitis C
and HIV-1 infection [28] and possibly vaccine-induced immunity
[43,44]. In contrast to the almost full recovery of pneumococcal
(D39)-specific polyfunctional T cell responses, D39Ply- responses
remained defective. These data were consistent with the IFN-c
ELISpot data which showed little recovery of D39Ply- IFN-c
ELISpot responses at 12 months ART. These data also fits well
with what we have shown before that immune memory to the
pneumococcus is differentially influenced by antigen [10].
Therefore, the role of pneumococcal protein antigens in immune
recovery during ART requires further investigation.
Figure 4. Functionality of CD4+ T cell during ART. Patients were analysed prior to initiation of ART and followed-up at 3, 6 and 12 mths ART for
different combinations of IFN-c, TNF-a and IL-2 using flow cytometry. Polyfunctional CD4+ T-cell profiles of HIV-infected persons on ART were
compared with HIV-negative persons recruited from the same community. CD4+ T-cell responses to (A) wild-type Streptococcus pneumoniae strain
concentrated culture supernatant (CCS) (D39WT CCS) (B) an isogenic pneumolysin (ply)-deficient mutant (D39Ply- CCS) (C) Influenza vaccine (D) M.
tuberculosis PPD. Collated data (background responses in the negative control substrated and threshold set at 0.01%) from HIV negative (n = 9) and
those infected with HIV (n = 18). Pies were analysed according to slice colour using SPICE software and p values are indicated. The frequency of CD4+
T cells producing one, two or three cytokines specific for D39WT CCS, D39Ply- CCS, influenza vaccine and PPD are shown in Figure S2.
doi:10.1371/journal.pone.0100640.g004
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When this study was started, most patients were starting ART
with CD4 T-cell counts less than 200 cells/ml. However, recently
more patients are being started on therapy at high CD4 T-cell
counts and therefore whether the observations we report here also
hold true for these patients will need to be confirmed.
In conclusion, we have demonstrated poor control of pneumo-
coccal colonization in HIV-infected persons which persists despite
ART. Despite some restoration of pneumococcal-specific CD4 T-
cell proliferation, we found impaired pneumococcal-specific
CD154 expression as well as incomplete recovery of D39Ply-
IFN-c ELISpot responses and CD4 T-cell polyfunctionality. These
results together with observations we have made previously
[11,17] provide the rationale for further longitudinal studies of
pneumococcal carriage and immunity to better define the
mechanisms of immune control. In particular, to explore the
relationship between pneumococcal-specific cellular immunity
detected in the blood, and pathogen clearance and immune
surveillance at the mucosal surface in both immunocompetent and
immunocompromised hosts.
Supporting Information
Figure S1 Representative flow cytometric data (CD4+ T
cells) and gating strategy (A) Plot showing naive and memory
CD4 T-cell subsets gated on characteristic expression patterns of
CD45RA and CCR7 (Upper left quadrant TCM - central memory
CD4+ T cells, lower left quadrant TEM – effector memory CD4
+ T
cells and upper right quadrant TN– naive CD4
+ T cells) in
peripheral blood (B) Plot showing phenotypic analysis of CD25
and FoxP3 expression in peripheral blood (c) Plots showing
expression of CD69 and CD154 in media only, pneumococcal
antigens, M. tuberculosis PPD and PHA (D) CD4+ T-cell
proliferative responses in media, pneumococcal antigens, M.
tuberculosis PPD and PHA (e) Plots showing cytokine expression
following stimulation with pneumococcal antigens and M.
tuberculosis PPD.
(TIF)
Figure S2 Functionality of CD4+ T cells after ART.
Patients were analyses prior to initiation of ART and followed-up
at 3, 6 and 12 mths ART for different combinations of IFN-c,
TNF-a and IL-2 using flow cytometry and SPICE software
(version 4). Charts show the frequency of CD4+ T cells producing
one, two or three cytokines specific for (A) wild-type Streptococcus
pneumoniae strain concentrated culture supernatant (CCS) (D39WT
CCS) (B) an isogenic pneumolysin (ply)-deficient mutant (D39Ply-
CCS) (C) Influenza antigens (D) M. tuberculosis PPD.
(TIF)
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